Abstract
Lactobacilli have beneficial effects on the digestive and immune systems. Surface layer protein SlpA is a key factor in probiotic–host crosstalk; however, how this immunomodulation affected by Lactobacillus SlpA is not yet well understood. In a LPS-induced RAW 264.7 cell model, SlpA derived from Lactobacillus acidophilus CICC 6074 significantly reduced the inflammatory responses as evidenced by inhibition of the production of inflammatory mediators such as iNOS and COX-2 and inflammatory cytokines, including TNF-α, IL-10, IL-1β, IFN-α and IFN-β, which may associate with TLR4-dependent MAPK and NF-κB as well as intracellular NOD2- and NLRP3-related signaling inactivation. Most importantly, SlpA ameliorates DSS-induced mice colitis indicated by reduced colitis symptoms including body weight loss, colonic atrophy and colonic mucosal damage, which may owe to a decrease in inflammatory cytokines. These findings suggest that SlpA has an ameliorative effect on the inflammation response and therefore a potential therapeutic role in treating colitis.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.